Annexin Pharmaceuticals AB (publ) (STO:ANNX)
Sweden
· Delayed Price · Currency is SEK 14.40
-0.10 (-0.69%)
At close: Mar 9, 2026
STO:ANNX Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 27.4 | 16.34 | 21.42 | 31.11 | 49.48 | Upgrade
|
| Cash & Short-Term Investments | 27.4 | 16.34 | 21.42 | 31.11 | 49.48 | Upgrade
|
| Cash Growth | 67.69% | -23.71% | -31.17% | -37.12% | 172.88% | Upgrade
|
| Other Receivables | 0.38 | 0.42 | 2.63 | 1.86 | 1.02 | Upgrade
|
| Receivables | 0.38 | 0.42 | 2.63 | 1.86 | 1.02 | Upgrade
|
| Prepaid Expenses | 0.79 | 0.63 | 0.87 | 0.67 | 0.22 | Upgrade
|
| Total Current Assets | 28.57 | 17.38 | 24.92 | 33.65 | 50.72 | Upgrade
|
| Property, Plant & Equipment | 1.12 | 1.08 | 1.17 | 1.26 | 1.35 | Upgrade
|
| Long-Term Investments | 0.31 | 0.31 | 0.31 | 0.41 | 0.15 | Upgrade
|
| Other Intangible Assets | 0.16 | 0.27 | 0.37 | 0.47 | 0.58 | Upgrade
|
| Other Long-Term Assets | - | - | - | 0.89 | - | Upgrade
|
| Total Assets | 30.16 | 19.04 | 26.76 | 36.68 | 52.79 | Upgrade
|
| Accounts Payable | 2.97 | 2.96 | 4.33 | 3.33 | 3.51 | Upgrade
|
| Accrued Expenses | 1.93 | 1.98 | 3.3 | 2.43 | 1.7 | Upgrade
|
| Other Current Liabilities | 0.33 | 0.39 | 0.32 | 0.77 | 0.84 | Upgrade
|
| Total Current Liabilities | 5.22 | 5.32 | 7.95 | 6.53 | 6.06 | Upgrade
|
| Total Liabilities | 5.22 | 5.32 | 7.95 | 6.53 | 6.06 | Upgrade
|
| Common Stock | 11.68 | 8.82 | 5.74 | 2.56 | 27.45 | Upgrade
|
| Additional Paid-In Capital | 386.61 | 341.36 | 299.29 | 269.63 | 220.91 | Upgrade
|
| Retained Earnings | -373.36 | -336.46 | -286.21 | -242.16 | -201.63 | Upgrade
|
| Comprehensive Income & Other | - | - | - | 0.12 | - | Upgrade
|
| Shareholders' Equity | 24.93 | 13.71 | 18.81 | 30.15 | 46.73 | Upgrade
|
| Total Liabilities & Equity | 30.16 | 19.04 | 26.76 | 36.68 | 52.79 | Upgrade
|
| Net Cash (Debt) | 27.4 | 16.34 | 21.42 | 31.11 | 49.48 | Upgrade
|
| Net Cash Growth | 67.69% | -23.71% | -31.17% | -37.12% | 172.88% | Upgrade
|
| Net Cash Per Share | 4.14 | 3.61 | 12.82 | 21.27 | 60.31 | Upgrade
|
| Filing Date Shares Outstanding | 7.06 | 5.33 | 3.47 | 1.54 | 1.37 | Upgrade
|
| Total Common Shares Outstanding | 7.06 | 5.33 | 3.47 | 1.54 | 1.37 | Upgrade
|
| Working Capital | 23.34 | 12.06 | 16.97 | 27.12 | 44.66 | Upgrade
|
| Book Value Per Share | 3.53 | 2.57 | 5.43 | 19.52 | 34.05 | Upgrade
|
| Tangible Book Value | 24.77 | 13.45 | 18.44 | 29.68 | 46.15 | Upgrade
|
| Tangible Book Value Per Share | 3.51 | 2.52 | 5.32 | 19.21 | 33.63 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.